Research programme: immuno-oncology therapeutics - Cue Biopharma

Drug Profile

Research programme: immuno-oncology therapeutics - Cue Biopharma

Alternative Names: CUE 101; CUE 102

Latest Information Update: 07 Apr 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Cue Biopharma
  • Class Antineoplastics; Immunotherapies
  • Mechanism of Action CD27 antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Autoimmune disorders; Cancer

Most Recent Events

  • 06 Apr 2017 Immuno-oncology therapeutics - Cue Biopharma is available for licensing as of 01 Mar 2017. https://www.cuebiopharma.com/business-development
  • 03 Mar 2017 Cue Biopharma intends to file an IND application for CUE 101 and CUE 102 for Cancer in 2017 (Cue Biopharma pipeline, March 2017)
  • 22 Feb 2017 Preclinical trials in Autoimmune disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top